Effect of alemtuzumab on intestinal intraepithelial lymphocytes and intestinal barrier function in cynomolgus model

Chinese Medical Journal

Volumn 128, Issue 5, 2015, Pages 680-686

  Qu, Lin Lin ^a   Lyu, Ya Qing ^a   Jiang, Hai Tao ^a   Shan, Ting ^b   Zhang, Jing Bin ^b   Li, Qiu Rong ^b   Li, Jie Shou ^b  

^a QINGDAO UNIVERSITY   (China)

^b JINLING HOSPITAL   (China)

Author keywords

Alemtuzumab; Barrier function; Infection; Intestinal intraepithelial lymphocytes; Lymphocyte depletion

Indexed keywords

ALEMTUZUMAB; ENDOTOXIN; LACTIC ACID; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INDUCED DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HISTOLOGY; IMMUNOTHERAPY; INFECTION; INTESTINE EPITHELIUM; INTESTINE MUCOSA PERMEABILITY; INTESTINE RESECTION; INTESTINE WALL; LYMPHOCYTE; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MACACA FASCICULARIS; MALE; MORPHOLOGY; NONHUMAN; PERMEABILITY BARRIER; SPECTROPHOTOMETRY; TIGHT JUNCTION; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; CYTOLOGY; DRUG EFFECTS; INTESTINE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; APOPTOSIS; FLOW CYTOMETRY; INTESTINES; LYMPHOCYTES; MACACA FASCICULARIS; MALE; MICROSCOPY, ELECTRON, TRANSMISSION;

EID: 84923366257     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.4103/0366-6999.151675     Document Type: Article

References (26)

1. 1. Demko S, Summers J, Keegan P, Pazdur R. FDA drug approval summary: Alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia. Oncologist 2008;13:167-74.
2. Ho VT, Cutler C. Current and novel therapies in acute GVHD. Best Pract Res Clin Haematol 2008;21:223-37.
3. Rowan W, Tite J, Topley P, Brett SJ. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology 1998;95:427-36.
4. Villamor N, Montserrat E, Colomer D. Mechanism of action and resistance to monoclonal antibody therapy. Semin Oncol 2003;30:424-33.
5. 5. Fraser G, Smith CA, Imrie K, Meyer R, Hematology Disease Site Group of Cancer Care Ontario’s Program in Evidence-based Care. Alemtuzumab in chronic lymphocytic leukemia. Curr Oncol 2007;14:96-109.
6. Novitzky N, Rouskova A. Infectious complications following T-cell depleted hematopoietic stem-cell transplantation. Cytotherapy 2001;3:165-73.
7. Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006;43:16-24.
8. Zanfi C, Lauro A, Cescon M, Dazzi A, Ercolani G, Grazi GL, et al. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: Rejection and infection rates in 40 recipients during the early postoperative period. Transplant Proc 2010;42:35-8.
9. Lepage AC, Buzoni-Gatel D, Bout DT, Kasper LH. Gut-derived intraepithelial lymphocytes induce long term immunity against Toxoplasma gondii. J Immunol 1998;161:4902-8.
10. Qu L, Li Q, Jiang H, Gu L, Zhang Q, Wang C, et al. Effect of anti-mouse CD52 monoclonal antibody on mouse intestinal intraepithelial lymphocytes. Transplantation 2009;88:766-72.
11. Hale G. CD52 (CAMPATH1). J Biol Regul Homeost Agents 2001;15:386-91.
12. Loisel S, Ohresser M, Pallardy M, Daydé D, Berthou C, Cartron G, et al. Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. Crit Rev Oncol Hematol 2007;62:34-42.
13. Zeitz M, Greene WC, Peffer NJ, James SP. Lymphocytes isolated from the intestinal lamina propria of normal nonhuman primates have increased expression of genes associated with T-cell activation. Gastroenterology 1988;94:647-55.
14. Tzakis AG, Kato T, Nishida S, Levi DM, Madariaga JR, Nery JR, et al. Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation. Transplantation 2003;75:1227-31.
15. Stanglmaier M, Reis S, Hallek M. Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann Hematol 2004;83:634-45.
16. Nainani N, Singh N, Shanahan T, Damodar A, Parimoo N, Ummadi S, et al. Cross reactive epitope group antibodies in sensitized kidneys transplant recipients was associated with early acute antibody mediated rejection. Transpl Immunol 2009;20:113-7.
17. Lü TM, Yang SL, Wu WZ, Tan JM. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients. Chin Med J 2011;124:664-8.
18. Nückel H, Frey UH, Röth A, Dührsen U, Siffert W. Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity. Eur J Pharmacol 2005;514:217-24.
19. Shapiro R, Basu A, Tan H, Gray E, Kahn A, Randhawa P, et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg 2005;200:505-15.
20. 20. Arnold R, Bunjes D, Wiesneth M, Hertenstein B, Theobald M, Heimpel H, et al. In vitro and in vivo depletion of T cells. Bone Marrow Transplant 1993;12 Suppl 3:S11-2.
21. 21. Beagley KW, Husband AJ. Intraepithelial lymphocytes: Origins, distribution, and function. Crit Rev Immunol 1998;18:237-54.
22. Cheroutre H, Kronenberg M. Mucosal T lymphocytes – Peacekeepers and warriors. Springer Semin Immunopathol 2005;27:147-65.
23. Komano H, Fujiura Y, Kawaguchi M, Matsumoto S, Hashimoto Y, Obana S, et al. Homeostatic regulation of intestinal epithelia by intraepithelial gamma delta T cells. Proc Natl Acad Sci U S A 1995;92:6147-51.
24. Tang SC, Hewitt K, Reis MD, Berinstein NL. Immunosuppressive toxicity of CAMPATH1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma. Leuk Lymphoma 1996;24:93-101.
25. Goteri G, Rupoli S, Tassetti A, Pulini S, Morichetti D, Filosa A, et al. Severe diarrhoea during Campath-1H treatment for refractory cutaneous T-cell lymphoma. Ann Hematol 2006;85:617-9.
26. Murray MJ, Barbose JJ, Cobb CF. Serum D(-)-lactate levels as a predictor of acute intestinal ischemia in a rat model. J Surg Res 1993;54:507-9.